AstraZeneca says FDA accepts application for Epanova AstraZeneca announced that the FDA has accepted for review a New Drug Application for Epanova, an investigational compound for the treatment for patients with severe hypertriglyceridaemia. The NDA submission for Epanova was filed by Omthera, now a wholly-owned subsidiary of AstraZeneca.T he Prescription Drug User Fee Act goal date for the FDA is May 5, 2014.
News For AZN From The Last 14 Days
Check below for free stories on AZN the last two weeks.
Leerink's biotech/pharma analysts hold an analyst/industry conference call Biotech Analyst Kozul and Major Pharmaceuticals Analyst Fernandez provide a review of Emerging 3rd Generation Tyrosine Kinas Inhibitors (TKI) Data for Non-Small Cell Lung Cancer (NSCLC) on an Analyst/Industry conference call. Relevant companies AstraZeneca (AZN) and Clovis Oncology (CLVS) may be discussed on the Analyst/Industry conference call to be held on December 12 at 1 pm.